BioNTech Unveils Modular mRNA Factories for Africa + FDA Authorizes Eli Lilly Monoclonal Antibody Effective Against Omicron episode artwork

EPISODE · Feb 23, 2022 · 25 MIN

BioNTech Unveils Modular mRNA Factories for Africa + FDA Authorizes Eli Lilly Monoclonal Antibody Effective Against Omicron

from Xtalks Life Science Podcast · host Xtalks

In this episode, Ayesha discussed BioNTech’s new modular mRNA factories, called the BioNTainer, that are destined for Africa to help boost COVID-19 vaccine supplies on the continent. The modular production units are housed in containers that come equipped with raw starting materials and state-of-the-art technology for producing mRNA-based vaccines from start to finish, except for the fill-and-finish step, which will be carried out by local manufacturers. Despite most African leaders welcoming the container factories, there is some controversy over BioNTech’s “paternalistic” control over production of its vaccine, especially since it continues to resist calls for patent waivers for its vaccine. The team also talked about Eli Lilly’s new COVID-19 monoclonal antibody bebtelovimab that received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) indicated for patients with mild to moderate COVID-19 who are at risk of progressing to severe disease. The treatment replaces Eli Lilly’s previous monoclonal antibody cocktail of bamlanivimab and etesevimab, which was pulled by the FDA over a lack of effectiveness against the Omicron variant. Lilly’s new monoclonal antibody has shown neutralizing activity against Omicron in lab studies so far. The US Department of Human Health Services (HHS) is making it available to patients free of charge. The team discussed how quickly the new monoclonal antibody was developed, showing that companies like Eli Lilly are continuing to work on new iterations of COVID-19 treatments and vaccines in the face of new emerging variants.   Read the full articles here:  BioNTech Unveils the BioNTainer, a Modular mRNA Vaccine Factory to Help Production in Africa FDA Authorizes Eli Lilly’s Bebtelovimab Which Demonstrates Activity Against Omicron For more life science and medical device content, visit the Xtalks Vitals homepage. Follow Us on Social Media Twitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Episode metadata supplied by the publisher feed · Published Feb 23, 2022

Embed this episode

NOW PLAYING

BioNTech Unveils Modular mRNA Factories for Africa + FDA Authorizes Eli Lilly Monoclonal Antibody Effective Against Omicron

0:00 25:58

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Xtalks Life Science Podcast?

This episode is 25 minutes long.

When was this Xtalks Life Science Podcast episode published?

This episode was published on February 23, 2022.

Can I download this Xtalks Life Science Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!